IR Insights: Recapping Business and Pipeline Updates from the 42nd Annual J.P. Morgan Healthcare Conference
Earlier today, Jamey Mock, Chief Financial Officer, presented an update on Moderna’s business and pipeline of mRNA development programs at the 42nd Annual J.P. Morgan Healthcare Conference.
Jamey sat down for an episode of IR Insights to give an overview of these updates, including Moderna’s 2023 performance, reiterated guidance for 2024-2026, and key upcoming milestones for the Company’s late-stage pipeline. Watch the episode here:
This post and the accompanying video contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna’s anticipated future revenues, sales growth, profitability, investment, cash balance and margins; the ability of Moderna’s existing cash balance to fund its current pipeline development; the potential timing for future product approvals and commercial launches; and the advancement of Moderna’s pipeline and late-stage programs, including the commencement of additional clinical trials. The forward-looking statements in this post are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include those other risks and uncertainties described under the heading “Risk Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this post in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date of this post.